Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Hyang Mi Ko"'
Autor:
Kirstin Perdrizet, Tracy L. Stockley, Jennifer H. Law, Adam Smith, Tong Zhang, Roxanne Fernandes, Muqdas Shabir, Peter Sabatini, Nadia Al Youssef, Christine Ishu, Janice JN Li, Ming-Sound Tsao, Prodipto Pal, Michael Cabanero, Joerg Schwock, Hyang Mi Ko, Scott Boerner, Heather Ruff, Frances A. Shepherd, Penelope A. Bradbury, Geoffrey Liu, Adrian G. Sacher, Natasha B. Leighl
Publikováno v:
Cancer Treatment and Research Communications, Vol 31, Iss , Pp 100534- (2022)
Objectives: Standard molecular testing for patients with stage IV non-small cell lung cancer (NSCLC) in the Canadian publicly funded health system includes single gene testing for EGFR, ALK, and ROS-1. Comprehensive genomic profiling (CGP) may broade
Externí odkaz:
https://doaj.org/article/efa5907711174a89a85365493ff18f7d
Autor:
Sally C.M. Lau, Madhumitha Rabindranath, Jessica Weiss, Janice J.N. Li, Andrea S. Fung, Dorinda Mullen, Najd Alshamlan, Heather M. Ruff, Leung Chu B. Tong, Prodipto Pal, Michael R. Cabanero, Ying-Han R. Hsu, Adrian G. Sacher, Frances A. Shepherd, Geoffrey Liu, Penelope A. Bradbury, Kazuhiro Yasufuku, Katarzyna Czarnecka-Kujawa, Hyang Mi Ko, Ming-Sound Tsao, Natasha B. Leighl, Joerg Schwock
Publikováno v:
Lung Cancer. 171:42-46
Testing for tumor programmed death ligand-1 (PD-L1) expression was initially developed with histology specimens in non-small cell lung cancer (NSCLC). However, cytology specimens are widely used for primary diagnosis and biomarker studies in clinical
Publikováno v:
Cytopathology. 33:389-392
Ewing sarcoma (ES) is the second most common bone malignancy in young patients, with 80% occurring in the first two decades of life. In contrast, extraskeletal ES accounts for approximately 12% of cases and is more common in older patients.[1] The cl
Autor:
Ilias P Nikas, Johannes A Vey, Tanja Proctor, Mousa M AlRawashdeh, Angela Ishak, Hyang Mi Ko, Han Suk Ryu
Publikováno v:
American journal of clinical pathology.
Objectives To perform the first meta-analysis regarding the pooled risk of malignancy (ROM) of each category of the Yokohama system for reporting breast fine-needle aspiration, as well as assess the latter’s diagnostic accuracy using this new syste
Autor:
Alexander Oberc, Kathleen Armstrong, Hyang-Mi Ko, Allison Grant, J. Brendan M. Mullen, Phillip Williams
Publikováno v:
International journal of surgery case reports. 93
Granular cell tumors (GCTs) can be diagnostically challenging due to their rarity, diverse anatomic locations, and clinical and radiologic similarities to other more common entities. GCTs involving the breast are rare and are most commonly encountere
Autor:
Prashant Bavi, Serra Stefano, Joerg Schwock, Zeina Ghorab, Hyang Mi Ko, James Cotton, Paul D. James
Publikováno v:
Cytopathology. 32:674-676
Autor:
Joerg Schwock, Hyang Mi Ko, Kazuhiro Yasufuku, Katarzyna Czarnecka-Kujawa, Si Kei Lou, Jessica Weiss, Scott MacDonald, Tomonari Kinoshita, Ming-Sound Tsao, Scott L. Boerner
Publikováno v:
Acta Cytologica. 64:577-587
Background: Programmed death ligand-1 (PD-L1) assessed by immunohistochemistry (IHC) is used as biomarker for pembrolizumab therapy in advanced stage lung cancer patients. However, data permitting direct performance comparison between cytology and su
Publikováno v:
Cytopathology. 30:653-656
Autor:
Asghar Naqvi, Michael Bonert, Christian Finley, Katarzyna Czarnecka-Kujawa, Kazuhiro Yasufuku, Vathany Kulasinngam, Rohan John, Joerg Schwock, Hyang-Mi Ko
Publikováno v:
Journal of the American Society of Cytopathology. 11:S53
Autor:
Joerg Schwock, Graeme Quest, Prodipto Pal, Ju-Yoon Yoon, Rakesh Nayyar, Hyang Mi Ko, Dana Pabedinskas, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 148
Objectives Pathologists encounter several challenges with programmed death ligand-1 (PD-L1) immunohistochemistry (IHC) tests in malignant effusions, including lineage specification (distinction between carcinoma vs. immune and mesothelial cells), bac